Awaiting development: Guidance and quality standards

Showing 21 to 30 of 87

Guidance and quality standards awaiting development
Title	Type
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]	Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]	Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]	Technology appraisal guidance
Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [TSID12390]	Technology appraisal guidance
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]	Technology appraisal guidance
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]	Technology appraisal guidance
Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]	Technology appraisal guidance
Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies	HealthTech guidance
Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [TSID12379]	Technology appraisal guidance